首页> 外国专利> LENTIVIRAL VECTOR FOR SPECIFICALLY KNOCKING DOWN HUMAN MIRNA-29A AND MIR-140 EXPRESSIONS, AND APPLICATION THEREOF

LENTIVIRAL VECTOR FOR SPECIFICALLY KNOCKING DOWN HUMAN MIRNA-29A AND MIR-140 EXPRESSIONS, AND APPLICATION THEREOF

机译:用于特定人类miRNA-29A和MIR-140表达的慢病毒载体及其应用

摘要

A lentiviral vector for specifically knocking down human miRNA-29a and miR-140 expressions, and application thereof. The lentiviral vector comprises a fundamental sequence, a resistance gene sequence, a multiple cloning site sequence, a promoter sequence, and an oligonucleotide sequence targeting miR-29a and miR-140 of a pLKO.1-puro expression vector. A multiple cloning site comprises an Age I enzyme cutting site and an EcoR I enzyme cutting site; the oligonucleotide sequence targeting miR-29a and miR-140 is inserted into the multiple cloning site in sense orientation. A pLKO-Tud-29a-140 lentiviral expression vector has the advantages of high transfection efficiency, a small amount required, and continuous, efficient, stable and specific inhibition in human miRNA-29a-140 expression, and may serve as a powerful tool for preparing drugs for treating diseases related to abnormal miRNA-29a-140 expression.
机译:用于特异性敲低人miRNA-29a和miR-140表达的慢病毒载体及其应用。慢病毒载体包含靶向pLKO.1-puro表达载体的miR-29a和miR-140的基本序列,抗性基因序列,多克隆位点序列,启动子序列和寡核苷酸序列。多克隆位点包括Age I酶切位点和EcoR I酶切位点。将靶向miR-29a和miR-140的寡核苷酸序列以有义方向插入到多克隆位点中。 pLKO-Tud-29a-140慢病毒表达载体具有转染效率高,所需量少,对人miRNA-29a-140表达具有连续,高效,稳定和特异性抑制的优点,可作为一种强大的工具用于制备用于治疗与miRNA-29a-140表达异常有关的疾病的药物。

著录项

  • 公开/公告号WO2017219165A1

    专利类型

  • 公开/公告日2017-12-28

    原文格式PDF

  • 申请/专利权人 MAO KANLANG;

    申请/专利号WO2016CN86331

  • 发明设计人 MAO KANLANG;

    申请日2016-06-19

  • 分类号C12N15/867;C12N15/66;

  • 国家 WO

  • 入库时间 2022-08-21 12:46:42

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号